JP2007510661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510661A5 JP2007510661A5 JP2006538492A JP2006538492A JP2007510661A5 JP 2007510661 A5 JP2007510661 A5 JP 2007510661A5 JP 2006538492 A JP2006538492 A JP 2006538492A JP 2006538492 A JP2006538492 A JP 2006538492A JP 2007510661 A5 JP2007510661 A5 JP 2007510661A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- composition
- medicament
- estrogen
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 29
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 28
- 239000002246 antineoplastic agent Substances 0.000 claims 27
- 229940127089 cytotoxic agent Drugs 0.000 claims 27
- 229940046836 anti-estrogen Drugs 0.000 claims 26
- 230000001833 anti-estrogenic effect Effects 0.000 claims 26
- 239000000328 estrogen antagonist Substances 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 24
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 20
- 239000003886 aromatase inhibitor Substances 0.000 claims 20
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 16
- 229960001603 tamoxifen Drugs 0.000 claims 14
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 13
- 229960002258 fulvestrant Drugs 0.000 claims 13
- 229960004622 raloxifene Drugs 0.000 claims 12
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 12
- 108010069236 Goserelin Proteins 0.000 claims 10
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 10
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 10
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 10
- 108010000817 Leuprolide Proteins 0.000 claims 10
- 229960000397 bevacizumab Drugs 0.000 claims 10
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 10
- 229960001467 bortezomib Drugs 0.000 claims 10
- 229960005395 cetuximab Drugs 0.000 claims 10
- 229960001433 erlotinib Drugs 0.000 claims 10
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 10
- 229960002584 gefitinib Drugs 0.000 claims 10
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 10
- 229960002913 goserelin Drugs 0.000 claims 10
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 10
- 229960004338 leuprorelin Drugs 0.000 claims 10
- 229960000575 trastuzumab Drugs 0.000 claims 10
- 239000002434 gonadorelin derivative Substances 0.000 claims 9
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 9
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 8
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 8
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 8
- 229960002932 anastrozole Drugs 0.000 claims 8
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 8
- 229960000255 exemestane Drugs 0.000 claims 8
- 229950011548 fadrozole Drugs 0.000 claims 8
- 229960004421 formestane Drugs 0.000 claims 8
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 8
- 229960003881 letrozole Drugs 0.000 claims 8
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 8
- 239000013059 antihormonal agent Substances 0.000 claims 6
- 229950002421 acolbifene Drugs 0.000 claims 3
- DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical group C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- -1 trastuzumab Chemical compound 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51782003P | 2003-11-06 | 2003-11-06 | |
| PCT/US2004/036859 WO2005046691A1 (en) | 2003-11-06 | 2004-11-04 | Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510661A JP2007510661A (ja) | 2007-04-26 |
| JP2007510661A5 true JP2007510661A5 (https=) | 2007-12-20 |
Family
ID=34590193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538492A Pending JP2007510661A (ja) | 2003-11-06 | 2004-11-04 | 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050119188A1 (https=) |
| EP (1) | EP1680118A1 (https=) |
| JP (1) | JP2007510661A (https=) |
| CN (1) | CN1917877A (https=) |
| AU (1) | AU2004289256A1 (https=) |
| BR (1) | BRPI0416316A (https=) |
| CA (1) | CA2544421A1 (https=) |
| MX (1) | MXPA06005031A (https=) |
| NO (1) | NO20062582L (https=) |
| TW (1) | TW200526215A (https=) |
| WO (1) | WO2005046691A1 (https=) |
| ZA (1) | ZA200603597B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060024691A1 (en) * | 2004-03-25 | 2006-02-02 | Buck Institute For Age Research | Novel pathways in the etiology of cancer |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| WO2009145852A1 (en) * | 2008-04-17 | 2009-12-03 | Concert Pharmaceuticals, Inc. | Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof |
| EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
| SI1255537T1 (sl) * | 2000-02-04 | 2006-10-31 | Janssen Pharmaceutica Nv | Inhibitorji farnezil protein transferaze za zdravljenje raka dojk |
| US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| CA2424797C (en) * | 2000-10-05 | 2009-12-29 | George Q. Daley | Methods of inducing cancer cell death and tumor regression |
| DE60230017D1 (de) * | 2001-02-15 | 2009-01-08 | Janssen Pharmaceutica Nv | Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen |
| WO2003047697A2 (en) * | 2001-11-30 | 2003-06-12 | Schering Corporation | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| AU2002346644A1 (en) * | 2001-12-03 | 2003-06-17 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
-
2004
- 2004-11-04 JP JP2006538492A patent/JP2007510661A/ja active Pending
- 2004-11-04 US US10/980,915 patent/US20050119188A1/en not_active Abandoned
- 2004-11-04 AU AU2004289256A patent/AU2004289256A1/en not_active Abandoned
- 2004-11-04 WO PCT/US2004/036859 patent/WO2005046691A1/en not_active Ceased
- 2004-11-04 CN CNA2004800323958A patent/CN1917877A/zh active Pending
- 2004-11-04 MX MXPA06005031A patent/MXPA06005031A/es unknown
- 2004-11-04 TW TW093133659A patent/TW200526215A/zh unknown
- 2004-11-04 EP EP04810378A patent/EP1680118A1/en not_active Withdrawn
- 2004-11-04 BR BRPI0416316-8A patent/BRPI0416316A/pt not_active IP Right Cessation
- 2004-11-04 CA CA002544421A patent/CA2544421A1/en not_active Abandoned
-
2006
- 2006-05-05 ZA ZA200603597A patent/ZA200603597B/en unknown
- 2006-06-02 NO NO20062582A patent/NO20062582L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2792848T3 (es) | Politerapia para el tratamiento de infecciones por VHB | |
| JP2021525248A5 (https=) | ||
| JP2016506916A5 (https=) | ||
| JP2007529421A5 (https=) | ||
| JP2018530549A5 (https=) | ||
| JP2014511383A5 (https=) | ||
| AR049200A1 (es) | Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20 | |
| JP2014533279A5 (https=) | ||
| JP2012525393A5 (https=) | ||
| IL292245B1 (en) | Polymorphic forms of rad1901-2hcl | |
| JP2010500370A5 (https=) | ||
| JPWO2019226761A5 (https=) | ||
| AR047962A1 (es) | Combinacion de agonistas de adrenoceptor beta-2 y corticosteroides para el tratamiento de enfermedades respiratorias | |
| RU2017116070A (ru) | Способ лечения первичного гормонорезистентного эндометриального рака и рака груди | |
| JP2022506829A (ja) | エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン | |
| JP2007510661A5 (https=) | ||
| JP2019501957A5 (https=) | ||
| CN1997374A (zh) | 雌激素受体调节剂 | |
| EA200501739A1 (ru) | Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний | |
| JP2003532737A5 (https=) | ||
| JP2020502106A5 (https=) | ||
| CA2423020C (en) | Use of antiprogestins for the induction of apoptosis in a cell | |
| JPWO2022053990A5 (https=) | ||
| JP2005508323A5 (https=) | ||
| JP2013512195A5 (https=) |